Biofilm Formation and its Impact on Antifungal Therapy

• Published in: Current fungal infection reports 2014-09, Vol.8 (3), p.235-241
• Main Author: Müller, Frank-Michael C.
• Format: Article
• Language: English
• Subjects: Advances in Diagnosis of Invasive Fungal Infections (U Binder; Infectious Diseases; Internal Medicine; Medicine; Medicine & Public Health; Occupational Medicine/Industrial Medicine; Pneumology/Respiratory System; Section Editor; Tropical Medicine
• ISSN: 1936-3761; 1936-377X
• DOI: 10.1007/s12281-014-0194-x

Fungi can protect themselves from host defences and antifungal drugs by the production of an extracellular hydrophobic matrix. Candida biofilms exhibit resistance to antifungal agents from all classes including the azoles, echinocandins, amphotericin B complex, and flucytosine. Although demonstrated on polystyrene and bronchial epithelia cells, until today, only indirect evidence for A. fumigatus biofilms in patients is available. The antifungals with the most activity against biofilms are the liposomal formulation of amphotericin B and agents in the echinocandin drug class. Importantly, echinocandins show excellent anti-biofilm activity against C. albicans at therapeutic concentrations. However, other biofilms formed by moulds, including A. fumigatus , are relatively resistant to echinocandins. Multiple mechanisms contribute to the intrinsic and acquired antifungal resistance during the different stages of fungal biofilm development. During the growth phase of the early biofilm various factors account for biofilm resistance. Combinational and sequential antifungal therapy as well as combination with enhancers can improve the effect of a single drug. Further studies are warranted to develop new therapeutic strategies targeting fungal biofilm-specific resistance mechanisms.